|  |
| --- |
| **Supplementary Table 1. Results of sensitivity analysis** |
| **Outcome** | **Omitted study (Year)** | **HR or RR (95% CI), *p*** | ***I*2, *p*** |
| OS | Zhu (2014) | HR=0.83, 0.71-0.97, 0.02 | 55%, 0.05 |
| Zhu (2015) | HR=0.87, 0.72-1.05, 0.14 | 68%, 0.008 |
| Bruix (2017) | HR=0.92, 0.81-1.03, 0.16 | 28%, 0.22 |
| Kudo (2017) | HR=0.87, 0.73-1.04, 0.13 | 68%, 0.008 |
| Rimassa (2018) | HR=0.85, 0.72-1.01, 0.07 | 66%, 0.01 |
| Zhu (2019) | HR=0.89, 0.76-1.05, 0.17 | 63%, 0.02 |
| Moehler (2019) | HR=0.84, 0.72-0.98, 0.03 | 62%, 0.02 |
| DCR | Llovet (2013) | RR=1.34, 1.11-1.61, 0.002 | 74%, 0.0008 |
| Zhu (2014) | RR=1.39, 1.14-1.68, 0.0009 | 74%, 0.0007 |
| Zhu (2015) | RR=1.39, 1.14-1.69, 0.0009 | 73%, 0.001 |
| Bruix (2017) | RR=1.30, 1.12-1.51, 0.0006 | 59%, 0.02 |
| Kudo (2017) | RR=1.33, 1.12-1.57, 0.001 | 72%, 0.001 |
| Rimassa (2018) | RR=1.44, 1.24-1.68, 0.00001 | 62%, 0.02 |
| Zhu (2019) | RR=1.34, 1.12-1.61, 0.001 | 74%, 0.0007 |
| Moehler (2019) | RR=1.39, 1.19-1.64, 0.0001 | 72%, 0.001 |
| TTP | Llovet (2013) | HR=0.66, 0.50-0.86, 0.002 | 87%, 0.00001 |
| Zhu (2014) | HR=0.60, 0.48-0.76, 0.0001 | 80%, 0.0001 |
| Zhu (2015) | HR=0.66, 0.49-0.88, 0.004 | 87%, 0.00001 |
| Bruix (2017) | HR=0.68 0.54-0.87, 0.002 | 81%, 0.0001 |
| Kudo (2017) | HR=0.65, 0.50-0.86, 0.002 | 87%, 0.00001 |
| Rimassa (2018) | HR=0.60, 0.48-0.76, 0.0001 | 82%, 0.00001 |
| Zhu (2019) | HR=0.68, 0.53-0.87, 0.002 | 85%, 0.00001 |
| Moehler (2019) | HR=0.62, 0.49-0.78, 0.0001 | 86%, 0.00001 |
| PFS | Zhu (2015) | HR=0.59, 0.41-0.84, 0.003 | 87%, 0.0001 |
| Bruix (2017) | HR=0.64, 0.48-0.85, 0.002 | 81%, 0.001 |
| Kudo (2017) | HR=0.60, 0.43-0.83, 0.002 | 87%, 0.0001 |
| Rimassa (2018) | HR=0.53, 0.45-0.64, 0.00001 | 55%, 0.08 |
| Zhu (2019) | HR=0.64, 0.48-0.85, 0.002 | 84%, 0.0002 |
| AEs of any grade | Llovet (2013) | RR=1.09, 1.03-1.15, 0.005 | 79%, 0.0007 |
| Zhu (2014) | RR=1.07, 0.98-1.17, 0.15 | 84%, 0.0001 |
| Bruix (2017) | RR=1.04, 0.95-1.15, 0.40 | 86%, 0.0001 |
| Kudo (2017) | RR=1.04, 0.98-1.11, 0.21 | 78%, 0.001 |
| Rimassa (2018) | RR=1.09, 1.01-1.17, 0.03 | 79%, 0.0007 |
| Moehler (2019) | RR=1.06, 0.99-1.13, 0.09 | 83%, 0.0001 |
| Decreased appetite | Llovet (2013) | RR=1.56, 1.09-2.26, 0.02 | 73%, 0.002 |
| Zhu (2014) | RR=1.47, 1.04-2.09, 0.03 | 66%, 0.01 |
| Zhu (2015) | RR=1.67, 1.16-2.41, 0.006 | 68%, 0.007 |
| Kudo (2017) | RR=1.44, 1.05-1.97, 0.03 | 61%, 0.03 |
| Rimassa (2018) | RR=1.73, 1.28-2.34, 0.0004 | 60%, 0.03 |
| Moehler (2019) | RR=1.51, 1.09-2.09, 0.01 | 71%, 0.004 |
| Diarrhea | Zhu (2019) | RR=1.83, 1.41-2.39, 0.00001 | 52%, 0.05 |
| Llovet (2013) | RR=1.73, 1.29-2.32, 0.0002 | 61%, 0.02 |
| Zhu (2014) | RR=1.69, 1.23-2.30, 0.001 | 61%, 0.02 |
| Zhu (2015) | RR=1.81, 1.37-2.41, 0. 0001 | 53%, 0.05 |
| Bruix (2017) | RR=1.59, 1.26-2.00, 0.0001 | 29%, 0.21 |
| Kudo (2017) | RR=1.62, 1.24-2.13, 0.0004 | 53%, 0.05 |
| Moehler (2019) | RR=1.79, 1.37-2.34, 0.0001 | 57%, 0.03 |
| Fatigue | Rimassa (2018) | RR=1.52, 1.21-1.92, 0.0004 | 53%, 0.05 |
| Zhu (2019) | RR=1.41, 1.09-1.82, 0.008 | 63%, 0.01 |
| Llovet (2013) | RR=1.43, 1.11-1.84, 0.006 | 64%, 0.010 |
| Zhu (2014) | RR=1.42, 1.09-1.86, 0.009 | 64%, 0.01 |
| Zhu (2015) | RR=1.51, 1.16-1.96, 0.002 | 59%, 0.02 |
| Bruix (2017) | RR=1.48, 1.11-1.98, 0.008 | 64%, 0.01 |
| Kudo (2017) | RR=1.27, 1.08-1.50, 0.004 | 17%, 0.30 |
| Moehler (2019) | RR=1.40, 1.11-1.76, 0.004 | 61%, 0.02 |
| Ascites | Rimassa (2018) | RR=1.41, 0.96-2.07, 0.08 | 73%, 0.003 |
| Zhu (2019) | RR=1.24, 0.88-1.76, 0.22 | 72%, 0.003 |
| Zhu (2014) | RR=1.41, 0.95-2.08, 0.09 | 73%, 0.003 |
| Zhu (2015) | RR=1.24, 0.86-1.79, 0.26 | 67%, 0.009 |
| Bruix (2017) | RR=1.41, 0.96-2.08, 0.03 | 72%, 0.003 |
| Kudo (2017) | RR=1.19, 0.87-1.64, 0.28 | 63%, 0.02 |
| Moehler (2019) | RR=1.42, 0.99-2.03, 0.05 | 72%, 0.003 |
| Vomiting | Zhu (2019) | RR=1.67, 1.04-2.67, 0.03 | 66%, 0.01 |
| Zhu (2014) | RR=1.67, 0.99-2.81, 0.05 | 66%, 0.01 |
| Zhu (2015) | RR=1.85, 1.39-2.47, 0.0001 | 0%, 0.68 |
| Bruix (2017) | RR=1.58, 0.98-2.56, 0.06 | 63%, 0.02 |
| Kudo (2017) | RR=1.44, 0.96-2.16, 0.08 | 53%, 0.06 |
| Zhu (2019) | RR=1.67, 1.04-2.67, 0.03 | 66%, 0.01 |
| Moehler (2019) | RR=1.55, 1.01-2.39, 0.04 | 63%, 0.02 |
| Constipation | Zhu (2014) | RR=1.18, 0.84-1.66, 0.34 | 43%, 0.13 |
| Zhu (2015) | RR=1.07, 0.68-1.68, 0.77 | 64%, 0.02 |
| Bruix (2017) | RR=0.96, 0.66-1.39, 0.83 | 48%, 0.10 |
| Kudo (2017) | RR=0.97, 0.68-1.39, 0.88 | 54%, 0.07 |
| Zhu (2019) | RR=1.16, 0.80-1.68, 0.42 | 52%, 0.08 |
| Moehler (2019) | RR=1.03, 0.71-1.50, 0.86 | 63%, 0.03 |
| AE, adverse event; CI, confidence interval; DCR, disease control rate; HR, hazard ratio; RR, relative risk; OS, overall survival; PFS, progression-free survival; TTP, time to progression. |